// App-Quantinova.ai

OT2-07-01 : A phase 2 study of futibatinib (TAS-120) in metastatic breast cancers harboring fibroblast growth factor receptor (FGFR) amplifications (FOENIX-MBC2)

Researchers

Presenter

  • Nick C. Turner

Principal Investigators

  • Ian E. Krop

  • Aditya Bardia

  • Senthil Damodaran

  • Miguel Martin

  • Karim A. Benhadji

  • Yaohua He

  • Mieke Ptaszynski

  • Carlos L. Arteaga

Medical Centers

  • The Institute of Cancer Research & The Royal Marsden, London, Spain

  • Dana-Farber Cancer Institute, Boston, MA

  • Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Universidad Complutense, CUBERONC, GEICAM, Madrid, Spain

  • Taiho Oncology Inc., Princeton, NJ

  • Simmons Cancer Center, UT Southwestern Medical Center, Dallas, TX

Locations

  • United Kingdom

  • United States

  • Spain

Companies

  • Taiho Oncology Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Fibroblast growth factor receptor

Drug/Treatment

  • TAS120

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • Taiho Oncology, Inc.

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved